#### Amendment

The following listing of claims will replace all prior versions and listings of claims in the application.

# Listing of the Claims:

- 1-12, (Canceled)
- 13. (Currently Amended) A vaccine for preventing infections with influenza virus comprising:

an influenza virus antigen;

a peptide (Peptide A) comprising a sequence KLKL<sub>3</sub>KLK (SEQ ID NO:6); and an immunostimulatory oligodeoxynucleic acid molecule (I-/U-ODN), wherein the I-/U-ODN comprises oligo d(IC)<sub>13</sub>, I-ODN2, or I-ODN2b.

$$\begin{array}{c|c} X_2 \\ \parallel \\ -X_1 \end{array} \qquad \begin{array}{c|c} X_2 \\ \parallel \\ -X_1 \end{array}$$

- 14. (Canceled)
- (Previously Presented) The vaccine of claim 13, further comprising an Al(OH)<sub>3</sub> adjuvant.

#### SN 10/550,754

## 16-17. (Canceled)

- 18. (Previously Presented) The vaccine of claim 13, wherein the influenza antigen is a haemagglutinin antigen or a neuraminidase antigen.
- 19. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide.
- 20. (Previously Presented) The vaccine of claim 13, wherein the I/U-ODN is oligo d(IC)<sub>13</sub>.
- 21. (Previously Presented) The vaccine of claim 13, further comprising an oligodeoxynucleotide containing a CpG-motif.
- 22. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.

### 23-28. (Canceled)

- 29. (Previously Presented) The vaccine of claim 13, wherein the I/U-ODN is I-ODN2
- 30. (Previously Presented) The vaccine of claim 13, wherein the I/U-ODN is I-ODN2b.